Literature DB >> 2715168

Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67.

M Deckert1, G Reifenberger, W Wechsler.   

Abstract

The proliferative activity of 133 human tumors of the nervous system was investigated by means of immunohistochemistry using the monoclonal antibody Ki-67 in order to evaluate the usefulness of this method for histopathological tumor grading. Ki-67 recognizes a proliferation-associated nuclear antigen present in human cells during all active phases of the cell cycle but absent in the G0 phase [Gerdes J, Schwab U, Lemke H, Stein H (1983) Int J Cancer 31:13-20]. In 28 WHO grade I and II gliomas of all major types Ki-67 indices were generally low with mean values ranging from less than 1% in pilocytic astrocytomas to 4.2% in grade II oligodendrogliomas. Individual cases of grade II astrocytomas and oligodendrogliomas had, however, values up to 8.5%. In 13 primary anaplastic gliomas of WHO grade III consistently higher statistical means were obtained with values ranging from 8.6% for anaplastic astrocytomas to 14.2% for anaplastic mixed gliomas. Interestingly, 18 WHO grade IV glioblastomas demonstrated a mean value of only 7%, which is probably due to the pronounced phenothypic heterogeneity in this tumor group. This heterogeneity results in enormous intra- and intertumor variability in Ki-67 indices (range less than 1%-22.1%). Investigation of 17 recurrent gliomas revealed mean values for Ki-67 ranging from 1.7% for three WHO grade II astrocytomas up to 48.5% obtained in two highly anaplastic recurrent astrocytomas corresponding to WHO grade IV. Other tumors of the nervous system evaluated included 9 medulloblastomas (mean 17.9%, range 5.0%-42.0%), 17 benign meningiomas (mean 1.1%, range 0%-5%), 15 metastatic carcinomas (mean 16.5%, range less than 1%-46.0%), and individual tumors of various types. Our results indicate that Ki-67 immunohistochemistry can add useful additional information for histopathological grading which, by supplementing and refining the traditional WHO grading system, might lead to a better assessment of the biological behaviour of human tumors of the nervous system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2715168     DOI: 10.1007/BF00397921

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

Review 1.  Morphological markers in neuro-oncology.

Authors:  P Kleihues; M Kiessling; R C Janzer
Journal:  Curr Top Pathol       Date:  1987

2.  The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology.

Authors:  P C Burger; T Shibata; P Kleihues
Journal:  Am J Surg Pathol       Date:  1986-09       Impact factor: 6.394

3.  [Autoradiographic studies of the growth of brain tumors using local labeling with 3H-thymidine in vivo].

Authors:  S Fukuma; S Taketomo; S Ueda; J Omachi; M Toyama
Journal:  No To Shinkei       Date:  1969-09

4.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

Review 5.  Differential expression of glial- and neuronal-associated antigens in human tumors of the central and peripheral nervous system.

Authors:  G Reifenberger; J Szymas; W Wechsler
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

6.  Proliferative potential of vascular components in human glioblastoma multiforme.

Authors:  T Nagashima; T Hoshino; K G Cho
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

7.  The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumours.

Authors:  C B Ostertag; B Volk; T Shibata; P Burger; P Kleihues
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

8.  Cell kinetic analyses of human malignant brain tumors (gliomas).

Authors:  T Hoshino; C B Wilson
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

9.  Growth rate of human pituitary adenomas.

Authors:  A M Landolt; T Shibata; P Kleihues
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

10.  In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.

Authors:  T Hoshino; T Nagashima; J A Murovic; C B Wilson; M S Edwards; P H Gutin; R L Davis; S J DeArmond
Journal:  J Neurosurg       Date:  1986-03       Impact factor: 5.115

View more
  24 in total

Review 1.  Metastatic adenocarcinoma in cerebral astrocytoma: clinicopathological and immunohistochemical study with review of the literature.

Authors:  Y Tajika; G Reifenberger; J C Kiwit; W Wechsler
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

2.  Correlation between nucleolar organizer region score and bromodeoxyuridine labeling index in C6 glioma cell line.

Authors:  A Hara; S Niikawa; H Hirayama; N Sakai; H Yamada; T Ohno; T Tanaka; H Mori
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

3.  Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices.

Authors:  V Vuorinen; P Sallinen; H Haapasalo; T Visakorpi; M Kallio; J Jääskeläinen
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

4.  Bardoxolone Methyl Prevents High-Fat Diet-Induced Colon Inflammation in Mice.

Authors:  Chi H L Dinh; Yinghua Yu; Alexander Szabo; Qingsheng Zhang; Peng Zhang; Xu-Feng Huang
Journal:  J Histochem Cytochem       Date:  2016-02-26       Impact factor: 2.479

5.  Transferrin receptor expression in tumours of the human nervous system: relation to tumour type, grading and tumour growth fraction.

Authors:  R Prior; G Reifenberger; W Wechsler
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

6.  The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients.

Authors:  Yuya Yoshida; Mitsutoshi Nakada; Tomoya Harada; Shingo Tanaka; Takuya Furuta; Yasuhiko Hayashi; Daisuke Kita; Naoyuki Uchiyama; Yutaka Hayashi; Jun-ichiro Hamada
Journal:  J Neurooncol       Date:  2009-11-25       Impact factor: 4.130

7.  Polyamine metabolism in gliomas.

Authors:  R I Ernestus; G Röhn; R Schröder; T Els; J Y Lee; N Klug; W Paschen
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

8.  Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods.

Authors:  K Onda; R L Davis; M S Edwards
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

9.  The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time.

Authors:  R Schröder; K Bien; R Kott; I Meyers; R Vössing
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Immunohistochemical determination of protein kinase C expression and proliferative activity in human brain tumors.

Authors:  G Reifenberger; M Deckert; W Wechsler
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.